| Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor V Rothhammer, ID Mascanfroni, L Bunse, MC Takenaka, JE Kenison, ... Nature medicine 22 (6), 586-597, 2016 | 1172 | 2016 |
| A vaccine targeting mutant IDH1 induces antitumour immunity T Schumacher, L Bunse, S Pusch, F Sahm, B Wiestler, J Quandt, O Menn, ... Nature 512 (7514), 324-327, 2014 | 766 | 2014 |
| Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 746 | 2019 |
| Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate L Bunse, S Pusch, T Bunse, F Sahm, K Sanghvi, M Friedrich, D Alansary, ... Nature medicine 24 (8), 1192-1203, 2018 | 422 | 2018 |
| A vaccine targeting mutant IDH1 in newly diagnosed glioma M Platten, L Bunse, A Wick, T Bunse, L Le Cornet, I Harting, F Sahm, ... Nature 592 (7854), 463-468, 2021 | 279 | 2021 |
| mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy M Weiler, J Blaes, S Pusch, F Sahm, M Czabanka, S Luger, L Bunse, ... Proceedings of the National Academy of Sciences 111 (1), 409-414, 2014 | 180 | 2014 |
| Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas M Friedrich, R Sankowski, L Bunse, M Kilian, E Green, ... Nature cancer 2 (7), 723-740, 2021 | 132 | 2021 |
| Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas K Aslan, V Turco, J Blobner, JK Sonner, AR Liuzzi, NG Núñez, D De Feo, ... Nature communications 11 (1), 931, 2020 | 131 | 2020 |
| K27M-mutant histone-3 as a novel target for glioma immunotherapy K Ochs, M Ott, T Bunse, F Sahm, L Bunse, K Deumelandt, JK Sonner, ... Oncoimmunology 6 (7), e1328340, 2017 | 99 | 2017 |
| The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway M Silginer, I Burghardt, D Gramatzki, L Bunse, H Leske, EJ Rushing, ... Oncogene 35 (25), 3260-3271, 2016 | 63 | 2016 |
| Suppression of TDO‐mediated tryptophan catabolism in glioblastoma cells by a steroid‐responsive FKBP52‐dependent pathway M Ott, UM Litzenburger, KJ Rauschenbach, L Bunse, K Ochs, F Sahm, ... Glia 63 (1), 78-90, 2015 | 63 | 2015 |
| The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients MJ Friedrich, P Neri, N Kehl, J Michel, S Steiger, M Kilian, N Leblay, ... Cancer Cell 41 (4), 711-725. e6, 2023 | 60 | 2023 |
| Proximity ligation assay evaluates IDH1R132H presentation in gliomas L Bunse, T Schumacher, F Sahm, S Pusch, I Oezen, K Rauschenbach, ... The Journal of Clinical Investigation 125 (2), 593-606, 2015 | 59 | 2015 |
| Concepts in glioma immunotherapy M Platten, L Bunse, W Wick, T Bunse Cancer Immunology, Immunotherapy 65, 1269-1275, 2016 | 55 | 2016 |
| Dysfunctional dendritic cells limit antigen-specific T cell response in glioma M Friedrich, M Hahn, J Michel, R Sankowski, M Kilian, N Kehl, M Günter, ... Neuro-oncology 25 (2), 263-276, 2023 | 33 | 2023 |
| Mutant IDH1: An immunotherapeutic target in tumors T Schumacher, L Bunse, W Wick, M Platten Oncoimmunology 3 (12), e974392, 2014 | 33 | 2014 |
| Expression and subcellular distribution of gephyrin in non-neuronal tissues and cells R Nawrotzki, M Islinger, I Vogel, A Völkl, J Kirsch Histochemistry and cell biology 137, 471-482, 2012 | 33 | 2012 |
| A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German … M Platten, D Schilling, L Bunse, A Wick, T Bunse, D Riehl, ... Journal of Clinical Oncology 36 (15_suppl), 2001-2001, 2018 | 27 | 2018 |
| MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors M Kilian, R Sheinin, CL Tan, M Friedrich, C Krämer, A Kaminitz, ... Cancer Cell 41 (2), 235-251. e9, 2023 | 25 | 2023 |
| Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas M Friedrich, L Bunse, W Wick, M Platten Current opinion in oncology 30 (6), 368-374, 2018 | 23 | 2018 |
